Diadexus, Inc. Highlights Upcoming Oral Presentation of Data From the PLAC(R) Activity Test Validation Study at the EAS Meeting
Oral Presentation on March 24, 2015 at 5:45 pm GMT
(firmenpresse) - SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 03/10/15 -- Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced that data validating the clinical performance of the PLAC® Test for Lp-PLA2 Activity (PLAC® Activity Test) has been accepted for oral presentation at the European Atherosclerosis Society 83rd Congress in Glasgow, UK from March 21-25, 2015. This will be the first presentation of clinical validation data evaluated by the U.S. Food and Drug Administration that led to 510(k) clearance of the PLAC Activity Test in December 2014.
Title: "Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity and coronary heart disease risk in a biracial cohort: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort"
Lead Author: Mary Cushman, M.D., M.Sc., Professor of Medicine and Pathology, Department of Medicine, University of Vermont
Time: March 24, 2015 at 5:45 pm Greenwich Mean Time (9:45 am Pacific Time)
For further information:
The PLAC® Test for Lp-PLA2 Activity, cleared by the U.S. FDA in December 2014, is to be used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk of coronary heart disease (CHD) in patients with no prior history of cardiovascular events, which represents approximately 75% of the U.S. population. Lp-PLA2 (lipoprotein-associated phospholipase A2) is a cardiovascular risk marker supported by a decade of peer-reviewed literature. Lp-PLA2 provides important new information about blood vessel inflammation, over and above the traditional risk factors measured on a lipid panel.
For more information about the test, visit .
Diadexus, based in South San Francisco, California, is a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, providing healthcare providers with actionable information for managing patients. The Company pioneered the testing of Lp-PLA2 (lipoprotein-associated phospholipase A2), a marker of vascular-specific inflammation that provides new information, over and above traditional risk factors measured in a lipid panel, and has over a decade of peer-reviewed literature validating this biomarker's utility. Diadexus' products are the only two FDA-cleared tests to measure Lp-PLA2: The PLAC® Test ELISA Kit first cleared by the FDA in 2003 and The PLAC® Test for Lp-PLA2 Activity cleared in December 2014.
The Company also has a pipeline of biomarkers for heart failure, proADM, proET-1 and proANP, with each providing distinct, additive information for healthcare providers over currently available markers. Diadexus also provides services to pharmaceutical partners to address the need to incorporate biomarkers in clinical development. For more information, please visit the Company's website at .
CONTACT:
Amy Figueroa, CFA
650-246-6424
Investor Relations and Corporate Communications
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 10.03.2015 - 20:00 Uhr
Sprache: Deutsch
News-ID 377492
Anzahl Zeichen: 0
contact information:
Town:
SOUTH SAN FRANCISCO, CA
Kategorie:
Healthcare
Diese Pressemitteilung wurde bisher 270 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Diadexus, Inc. Highlights Upcoming Oral Presentation of Data From the PLAC(R) Activity Test Validation Study at the EAS Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
Diadexus, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
